Assistant Professor, Harvard Medical School, Boston MA Director, Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center, Boston MA Associate Member, Broad Institute
The chromatin regulators CBP and p300 maintain gene expression programs through lysine acetylation of chromatin and transcriptional regulators and by scaffolding functions mediated by several protein-protein interaction domains. We have developed a chemical degrader of p300/CBP, dCBP-1, using in silico modeling and cellular activity assays including capillary-based immunodetection assays (ProteinSimple, WES). We have found that dCBP-1 is exceptionally potent at killing multiple myeloma cells and can abolish the enhancer that drive MYC oncogene expression. As an efficient degrader of this unique class of chromatin regulators, dCBP-1 will be a useful tool for understanding p300/CBP activity at enhancers in both normal and diseased cells.
Webinars will be available for unlimited on-demand viewing after live event.
In cell therapy applications, commonly employed cell purification platforms for large-scale isolation of immune or stem cells separate cells based on a single cell surface antigen. Enrichmen...
With advancing food allergy research and emerging therapies, new allergy testing requirements arise. In this context, Basophil Activation Testing (BAT) has emerged as an essential component...
Energy-efficient filtration solutions that reduce hidden chemical exposure from benchtop work and lab equipment to improve overall laboratory safety...
Discover how Iconeus One, the premier functional ultrasound (fUS) system for neuroscientists, is transforming brain function studies. Based on ultrafast plane-wave sonography, Iconeus One of...
The collection of high-quality genomic DNA remains a major barrier in pediatric and neurodevelopmental research, particularly among children with autism spectrum disorder (ASD) and other neu...